THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Monday, January 24, 2022
BrightInsight unveils its compliant and diverse Disease management solution that offers the fasted speed to market to support the highest regulated digital health software.
Fremont, CA: Several market variables drive the rising digital use of biopharma. As the cost of medication development rises, intensifying competition exerts pressure on drug pricing. Globally, poor therapy adherence costs the industry more than $600 billion every year. Even prior to the COVID Pandemic, consumers demanded flawless digital experiences from their service providers. Industry analysts anticipate that blockbuster pharmaceuticals will diminish as individualized and precise therapies with digital components and non-pharmaceutical digital therapeutics disrupt the biopharma sector. BrightInsight, the premier global platform for biopharma and medtech regulated digital health solutions, has launched its Disease Management Solution at BIO 2022. This flexible collection of digital applications consists of a Patient App, Analytics Dashboards, and Healthcare Provider Interfaces. Built on the compliant BrightInsight Platform on Google Cloud, the Disease Management Solution meets biopharma and medtech customers' core needs out-of-the-box to support the highest regulated digital health Software as a Medical Device (SaMD) classifications, engage patients and providers to improve outcomes and provide actionable data insights so customers can rapidly iterate and optimize digital health products.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
“We developed the BrightInsight Disease Management Solution to enable biopharma and medtech to accelerate time to market for SaMD and regulated digital solutions. Now, biopharma and medtech companies can configure our flexible, comprehensive solution to develop unique and highly differentiated digital offerings to transform how patients manage their conditions,” comments Kal Patel, M.D., CEO and Co-Founder. “Leveraging our Disease Management Solution, our clients can harness real-world data to demonstrate treatment value, differentiate their therapies and ultimately increase revenue. They are building regulated patient apps that support the patient care journey, including therapy administration guidance and tracking, ongoing disease monitoring, medication reminders, and communication with healthcare providers.”
“The biopharma industry is leveraging data and digital to accelerate drug development, improve therapy adherence and persistence, and enhance the patient journey, driving explosive growth in the regulated digital health market, which is expected to be a $56 billion global market by 2025,” states Karl Hick, former Chief Digital and Information Officer, Takeda, and member, BrightInsight Advisory Council. “For biopharma to build and launch regulated digital solutions efficiently and effectively, it will become critical to engage partners like BrightInsight with the experience, robust Professional Services, and proven platform and solutions to ensure speed to market in a compliant manner, at scale.”
More in News